首页> 美国卫生研究院文献>PLoS Clinical Trials >Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach
【2h】

Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach

机译:通过基于途径的表达谱分析方法估计吡咯-咪唑聚酰胺结合的全基因组脱靶效应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the search for new pharmaceutical leads, especially with DNA-binding molecules or genome editing methods, the issue of side and off-target effects have always been thorny in nature. A particular case is the investigation into the off-target effects of N-methylpyrrole-N-methylimidazole polyamides, a naturally inspired class of DNA binders with strong affinity to the minor-groove and sequence specificity, but at < 20 bases, their relatively short motifs also insinuate the possibility of non-unique genomic binding. Binding at non-intended loci potentially lead to the rise of off-target effects, issues that very few approaches are able to address to-date. We here report an analytical method to infer off-target binding, via expression profiling, based on probing the relative impact to various biochemical pathways; we also proposed an accompanying side effect prediction engine for the systematic screening of candidate polyamides. This method marks the first attempt in PI polyamide research to identify elements in biochemical pathways that are sensitive to the treatment of a candidate polyamide as an approach to infer possible off-target effects. Expression changes were then considered to assess possible outward phenotypic changes, manifested as side effects, should the same PI polyamide candidate be administered clinically. We validated some of these effects with a series of animal experiments, and found agreeable corroboration in certain side effects, such as changes in aspartate transaminase levels in ICR and nude mice post-administration.
机译:在寻找新的药物线索时,尤其是利用DNA结合分子或基因组编辑方法时,副作用和脱靶效应问题在本质上一直是棘手的。一个特殊的案例是研究N-甲基吡咯-N-甲基咪唑聚酰胺的脱靶作用,N-甲基吡咯-N-甲基咪唑聚酰胺是自然激发的一类DNA结合剂,对次要凹槽和序列特异性具有很强的亲和力,但在20个碱基以下,它们相对较短基序也暗示了非唯一基因组结合的可能性。在非预期基因座处的结合可能导致脱靶效应的增加,这是迄今为止很少有方法能够解决的问题。我们在此报告一种分析方法,该方法可基于表达对各种生化途径的相对影响来通过表达谱分析来推断脱靶结合。我们还提出了用于系统筛选候选聚酰胺的伴随副作用预测引擎。该方法标志着PI聚酰胺研究的首次尝试,即鉴定对候选聚酰胺的处理敏感的生化途径中的元素,以此作为推断可能的脱靶效应的方法。然后,如果临床上使用相同的PI聚酰胺候选人,则认为表达变化可评估可能的向外表型变化,表现为副作用。我们通过一系列动物实验验证了其中一些作用,并在某些副作用中发现了令人满意的佐证,例如给药后ICR和裸鼠中天冬氨酸转氨酶水平的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号